Document Type

Paper- Restricted to Campus Access

Publication Date

10-2025

Faculty Mentor

Denise Finney

Abstract

Most countries have created laws and regulatory bodies to rigorously monitor the use of animals, including NHPs, and ensure regulatory compliance in the biopharmaceutical research realm (Bayne et. al, 2023). The regulatory bodies’ oversight can vary, but generally includes mandating ethical sourcing of animals, humane housing and husbandry, scientific justification, procedural limitations, and extensive documentation. (Chatfield & Morton, 2018). In the United States, these government-created regulatory elements coexist with a multitude of professional bodies that have issued guidelines aimed at enhancing the care and well-being of nonhuman primates maintained in captivity (Bayne et. al, 2023). This includes preventative care and procedural care (National Research Council (US), 2011). The use of NHPs in biopharmaceutical research does not exist in a vacuum outside ethical scrutiny. In fact, many institutions, including the FDA support the use of scientifically sound alternatives to animal testing. However, validated options remain limited across much of preclinical research (FDA, 2025).

Comments

The item available here for download is an internship presentation poster.

Download

Restricted

Available to Ursinus community only.

Share

COinS